Clinical trials: B Cell ALL
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT02508038
- Testing
- TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Leukemia, Chronic Lymphatic
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
The aim of this study is to induce a peptide-specific immune response in CLL patients by multi-peptide vaccination with a patient-individualized peptide cocktail.
- Trial name
- NCT02802943
- Testing
- Peptide Vaccine, Imiquimod
- Where
- 5 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University Hospital Tuebingen
Non-Hodgkin's B-cell Lymphoma
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
This is an active treatment, extended access study open solely to those subjects who have successfully completed the Core and Repeat Dosing portions of the MT-3724_NHL_001_US clinical study and who, in the investigator's…
- Trial name
- NCT02715843
- Testing
- MT-3724
- Where
- 3 sites in United States
- Sponsor
- Molecular Templates, Inc.
Systemic Lupus Erythematosus
Humanized LL2IGG to Treat Systemic Lupus Erythematosus
This study will examine the safety of a new genetically engineered antibody called hLL2 (epratuzumab) in patients with systemic lupus erythematosus (SLE).
- Trial name
- NCT00011908
- Testing
- hLL2 (Epratuzumab)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Lymphoma
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more…
- Trial name
- NCT00003578
- Testing
- CHOP regimen, carmustine, cyclophosphamide
- Where
- 72 sites in Czechia, Denmark and 2 more
- Volunteers
- 500 people
- Sponsor
- Lymphoma Trials Office
Diffuse Large B-Cell Lymphoma
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of…
- Trial name
- NCT07059650
- Testing
- DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR
- Where
- 13 sites in China
- Volunteers
- 150 people
- Sponsor
- Dizal Pharmaceuticals
Extranodal NK/T-cell Lymphoma
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
Study Title: Phase I/II study of brentuximab vedotin and methotrexate/ L-asparaginase/ dexamethasone (B-MAD) chemotherapy in patients with newly-diagnosed Extranodal NK/T-cell Lymphoma Phase: I/II Number of Patients: 36 Study…
- Trial name
- NCT03246750
- Testing
- B-MAD chemotherapy
- Where
- Thailand
- Volunteers
- 34 people
- Sponsor
- The Thai Lymphoma Study Group
Antibody Mediated Rejection After Kidney Transplantation
Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity
Humoral rejection of kidney transplants is responsible for a large number of kidney graft losses in a context of increasing shortage.
- Trial name
- B-KiMi (NCT07134491)
- Testing
- Piece of kidney removal, Stool collection, Blood collection
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NSCLC, SCLC
Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer…
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
- Trial name
- NCT05546268
- Testing
- Oral MRT-2359
- Where
- 17 sites in United States
- Volunteers
- 174 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Leukemia
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00096018
- Testing
- fludarabine phosphate, thalidomide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Roswell Park Cancer Institute
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a…
- Trial name
- FIRCE-1 (NCT05972720)
- Testing
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Where
- 31 sites in United States
- Volunteers
- 101 people
- Sponsor
- CARGO Therapeutics
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes.
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT03959085
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Where
- 231 sites in United States, Australia and 3 more
- Volunteers
- 5,951 people
- Sponsor
- Children's Oncology Group
B Cell Non-Hodgkin's Lymphoma
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.
- Trial name
- NCT05149391
- Testing
- CD19/CD20-directed Chimeric Antigen Receptor T Cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University
Gastric Cancer, Head and Neck Cancer
Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating…
- Conditions
- Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01147991
- Testing
- EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine, laboratory biomarker analysis, pharmacological study
- Where
- 3 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Cancer Research UK
Leukemia
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003174
- Testing
- bryostatin 1, cladribine
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
B-cell Non-Hodgkin's Lymphoma (B-NHL)
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
The main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- XP-006 (NCT07334574)
- Testing
- Personalized neoantigen tumor vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
DLBCL - Diffuse Large B Cell Lymphoma
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
This is a single-center, single-arm, prospective study aimed at evaluating the efficacy and safety of orelabrutinib combined with an induction regimen followed by monotherapy maintenance in patients with MCD subtype diffuse large…
- Trial name
- NCT07677813
- Testing
- R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ou Bai, MD/PHD
Giant Cell Arteritis (GCA)
Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)
B cells are a component of the immune system which appear be important in causing all forms of cardiovascular disease. Until now, it has not been possible to directly study these cells in living patients (essential to assess…
- Trial name
- RituxiMAP GCA (NCT07269938)
- Testing
- Zirconium Zr 89 labelled rituximab
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Lymphoma, B-Cell
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?
The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy.
- Trial name
- NCT03681938
- Testing
- Autograft
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Institut Paoli-Calmettes
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01678443
- Testing
- indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center